Cytokinetics, Incorporated (NASDAQ:CYTK) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other brokerages have also recently commented on CYTK. Zacks Investment Research cut Cytokinetics, from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 4th. HC Wainwright set a $26.00 price objective on Cytokinetics, and gave the stock a “buy” rating in a research note on Thursday, August 3rd. BidaskClub upgraded Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Cowen and Company restated a “buy” rating and set a $19.00 price objective on shares of Cytokinetics, in a research note on Friday, August 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics, in a research note on Friday, May 19th. Three investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $21.30.

Cytokinetics, (CYTK) traded down 0.67% during trading on Friday, reaching $14.75. The company’s stock had a trading volume of 307,289 shares. Cytokinetics, has a 52 week low of $8.51 and a 52 week high of $17.20. The company has a 50 day moving average price of $13.45 and a 200-day moving average price of $13.28. The company’s market capitalization is $791.57 million.

Cytokinetics, (NASDAQ:CYTK) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.03. The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $5.28 million. Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. Equities research analysts anticipate that Cytokinetics, will post ($2.46) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/01/cytokinetics-incorporated-cytk-upgraded-at-valuengine.html.

In related news, insider Caryn Gordon Mcdowell sold 11,348 shares of the business’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $12.47, for a total value of $141,509.56. Following the transaction, the insider now owns 21,570 shares in the company, valued at $268,977.90. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Robert I. Blum sold 5,000 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $14.71, for a total value of $73,550.00. Following the completion of the transaction, the chief executive officer now owns 79,785 shares in the company, valued at approximately $1,173,637.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 154,678 shares of company stock worth $2,264,660. Insiders own 7.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue purchased a new stake in shares of Cytokinetics, during the second quarter valued at $109,000. Municipal Employees Retirement System of Michigan purchased a new stake in shares of Cytokinetics, during the second quarter valued at $132,000. LMR Partners LLP purchased a new stake in shares of Cytokinetics, during the first quarter valued at $156,000. Bank of America Corp DE raised its stake in shares of Cytokinetics, by 36.8% in the first quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 3,383 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Cytokinetics, by 4,464.4% in the second quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 13,036 shares in the last quarter. 71.51% of the stock is owned by hedge funds and other institutional investors.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.